董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Adi Raviv | 男 | Director | 70 | 未披露 | 66.80 | 2026-04-01 |
| Yael Margolin | 女 | Director | 72 | 未披露 | 66.80 | 2026-04-01 |
| Samuel Moed | 男 | Director | 63 | 未披露 | 未持股 | 2026-04-01 |
| Amir Reichman | 男 | Chief Executive Officer and Director | 50 | 52.60万 | 430.80 | 2026-04-01 |
| Jay Green | 男 | Director | 54 | 未披露 | 62.00 | 2026-04-01 |
| Mark Germain | 男 | Chairman of the Board | 75 | 43.20万 | 未持股 | 2026-04-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Elad Mark | 男 | Chief Operating Officer | 44 | 26.90万 | 85.56 | 2026-04-01 |
| Uri Ben Or | 男 | Chief Financial Officer | 55 | 17.90万 | 23.56 | 2026-04-01 |
| Amir Reichman | 男 | Chief Executive Officer and Director | 50 | 52.60万 | 430.80 | 2026-04-01 |
董事简历
中英对照 | 中文 | 英文- Adi Raviv
-
Adi Raviv是一名高级财务主管，职业生涯超过30年。自2016年4月起，Raviv先生一直担任Capacity Funding LLC的负责人，该公司为小型企业提供营运资金解决方案。在此之前，Raviv先生曾在另外两家提供类似融资选择的公司担任首席财务官职位，这两家公司分别是2015年5月至2016年3月的New Era Lending和2009年至2014年的Kapitus Forever，前者是战略资金来源。Raviv先生拥有广泛的资本市场，现金管理，企业融资，投资者关系，重组，税收和财政部，交易经验以及私募股权和风险投资领域的知识。Raviv先生联合创立了THCG，Inc.，这是一家公开交易的技术商人银行和咨询公司（在那里他也是首席财务官），并一直参与挑战初创公司，增长和周转环境的公司。Raviv先生曾在许多私人和几家上市公司，以及各种非营利实体的董事会任职。他在耶路撒冷希伯来大学（Hebrew University of Jerusalem）以优异成绩获得国际关系学士学位，并在纽约市哥伦比亚大学（Columbia University）以优异成绩获得工商管理硕士学位。
Adi Raviv joined the board of directors in 2020. Mr. Raviv is a senior financial executive with a career spanning over 35 years. He founded HTI Associates LLC in 1996 and since then has served as its managing member. In the past five years, and in the capacity of a consultant on behalf of HTI, Mr. Raviv has served as a Chief Executive Officer, Chief Financial Officer and Senior Advisor, respectively, to several healthcare and related companies, and continues to serve in a CFO role in one such company. In addition, since April 2016 he has been a Principal at Capacity Funding LLC, a company providing working capital solutions to small businesses. Prior to that, Mr. Raviv served in a chief financial officer position in two other companies that provide similar types of funding alternatives from 2009 to 2016. Mr. Raviv has extensive capital markets, cash management, corporate finance, investment banking, investor relations, restructuring, tax and treasury, and transactional experience along with knowledge of the private equity and venture capital arenas. Mr. Raviv co founded THCG, Inc., a publicly traded technology merchant banking and consulting company (where he was also CFO), and has been involved with companies in challenging startup, growth, and turnaround environments. He was also an investment banker at Lehman Brothers, Oscar Gruss and Hambros over a span of a dozen years. Mr. Raviv served on the boards of directors of many private and several public companies, as well as various non profit entities. He received a bachelor's degree in International Relations with honors from the Hebrew University of Jerusalem and an MBA, with honors, from Columbia University in New York City. - Adi Raviv是一名高级财务主管，职业生涯超过30年。自2016年4月起，Raviv先生一直担任Capacity Funding LLC的负责人，该公司为小型企业提供营运资金解决方案。在此之前，Raviv先生曾在另外两家提供类似融资选择的公司担任首席财务官职位，这两家公司分别是2015年5月至2016年3月的New Era Lending和2009年至2014年的Kapitus Forever，前者是战略资金来源。Raviv先生拥有广泛的资本市场，现金管理，企业融资，投资者关系，重组，税收和财政部，交易经验以及私募股权和风险投资领域的知识。Raviv先生联合创立了THCG，Inc.，这是一家公开交易的技术商人银行和咨询公司（在那里他也是首席财务官），并一直参与挑战初创公司，增长和周转环境的公司。Raviv先生曾在许多私人和几家上市公司，以及各种非营利实体的董事会任职。他在耶路撒冷希伯来大学（Hebrew University of Jerusalem）以优异成绩获得国际关系学士学位，并在纽约市哥伦比亚大学（Columbia University）以优异成绩获得工商管理硕士学位。
- Adi Raviv joined the board of directors in 2020. Mr. Raviv is a senior financial executive with a career spanning over 35 years. He founded HTI Associates LLC in 1996 and since then has served as its managing member. In the past five years, and in the capacity of a consultant on behalf of HTI, Mr. Raviv has served as a Chief Executive Officer, Chief Financial Officer and Senior Advisor, respectively, to several healthcare and related companies, and continues to serve in a CFO role in one such company. In addition, since April 2016 he has been a Principal at Capacity Funding LLC, a company providing working capital solutions to small businesses. Prior to that, Mr. Raviv served in a chief financial officer position in two other companies that provide similar types of funding alternatives from 2009 to 2016. Mr. Raviv has extensive capital markets, cash management, corporate finance, investment banking, investor relations, restructuring, tax and treasury, and transactional experience along with knowledge of the private equity and venture capital arenas. Mr. Raviv co founded THCG, Inc., a publicly traded technology merchant banking and consulting company (where he was also CFO), and has been involved with companies in challenging startup, growth, and turnaround environments. He was also an investment banker at Lehman Brothers, Oscar Gruss and Hambros over a span of a dozen years. Mr. Raviv served on the boards of directors of many private and several public companies, as well as various non profit entities. He received a bachelor's degree in International Relations with honors from the Hebrew University of Jerusalem and an MBA, with honors, from Columbia University in New York City.
- Yael Margolin
-
Yael Margolin在风险投资、制药和生物技术行业拥有超过35年的担任高级经理、首席执行官和董事会成员的经验，领导战略和业务规划、融资、团队建设、产品开发和企业伙伴关系。从2005年到2019年，Margolin博士担任临床阶段生物制药公司Gamida CellLtd.的总裁，首席执行官兼董事，领导公司从临床前开发到3期国际注册研究。在此之前，Margolin博士是专注于梦百合的风险投资公司Denali Ventures LLC的Vice President，也是Teva Pharmaceuticals的项目经理。Margolin博士持有以色列特拉维夫大学（Tel Aviv University）微生物系的生物学理学学士学位和理学硕士学位，以及雷霍沃特魏茨曼科学研究所（Weitzman Institute of Science）膜研究系的博士学位，Yael University School of Medicine的博士后。
Yael Margolin joined the board of directors in 2020. Dr. Margolin has more than 35 years of experience as senior manager, CEO and board member in venture capital and in the pharmaceutical and biotech industries, leading strategic and business planning, financing, team building, product development and corporate partnerships. From 2005 to 2019, Dr. Margolin served as President, Chief Executive Officer and director of Gamida Cell Ltd., a clinical stage biopharmaceutical company, leading the company from preclinical development through phase 3 international registration studies. Prior to that, Dr. Margolin was Vice President of Denali Ventures LLC, a venture capital firm focused on healthcare, and a program manager at Teva Pharmaceuticals. Dr. Margolin holds a bachelor of science in biology and a master of science Cum Laude from the department of microbiology, both from Tel Aviv University in Israel, a Ph.D. From the department of membrane research at the Weitzman Institute of Science in Rehovot, Israel and was a post doctoral associate at the Yale University School of Medicine. - Yael Margolin在风险投资、制药和生物技术行业拥有超过35年的担任高级经理、首席执行官和董事会成员的经验，领导战略和业务规划、融资、团队建设、产品开发和企业伙伴关系。从2005年到2019年，Margolin博士担任临床阶段生物制药公司Gamida CellLtd.的总裁，首席执行官兼董事，领导公司从临床前开发到3期国际注册研究。在此之前，Margolin博士是专注于梦百合的风险投资公司Denali Ventures LLC的Vice President，也是Teva Pharmaceuticals的项目经理。Margolin博士持有以色列特拉维夫大学（Tel Aviv University）微生物系的生物学理学学士学位和理学硕士学位，以及雷霍沃特魏茨曼科学研究所（Weitzman Institute of Science）膜研究系的博士学位，Yael University School of Medicine的博士后。
- Yael Margolin joined the board of directors in 2020. Dr. Margolin has more than 35 years of experience as senior manager, CEO and board member in venture capital and in the pharmaceutical and biotech industries, leading strategic and business planning, financing, team building, product development and corporate partnerships. From 2005 to 2019, Dr. Margolin served as President, Chief Executive Officer and director of Gamida Cell Ltd., a clinical stage biopharmaceutical company, leading the company from preclinical development through phase 3 international registration studies. Prior to that, Dr. Margolin was Vice President of Denali Ventures LLC, a venture capital firm focused on healthcare, and a program manager at Teva Pharmaceuticals. Dr. Margolin holds a bachelor of science in biology and a master of science Cum Laude from the department of microbiology, both from Tel Aviv University in Israel, a Ph.D. From the department of membrane research at the Weitzman Institute of Science in Rehovot, Israel and was a post doctoral associate at the Yale University School of Medicine.
- Samuel Moed
-
Samuel Moed在过去六年中担任百时美施贵宝公司（Bristol Myers Squibb“；BMS”；）的公司战略高级副总裁，，该公司是一家专注于创新疗法的全球性生物制药公司，他在该公司领导公司的战略方向，并与其所有主要业务、职能和地区保持密切联系。此前，Moed先生监管BMS&8217；s Worldwide Pharmaceuticals Group的战略，包括一系列全球战略举措，并管理战略联盟的全球投资组合。他还领导了多家企业，包括美国制药公司总裁和WW消费者梦百合总裁。Moed先生在纽约市哥伦比亚大学（Columbia University）获得历史学文学学士学位。
Samuel Moed joined the board of directors in 2020. Mr. Moed is a healthcare executive with over 35 years of experience. He was for seven years Head of Corporate Strategy at Bristol Myers Squibb ("BMS"), a global biopharma company, until his retirement in 2020. Prior to that role, Mr. Moed was Head of Strategy Worldwide Pharma, President of US Pharma and President of the WW Consumer Health care Business at BMS. In addition to Scinai, Mr. Moed serves on the board of Mediwound Ltd., a company that develops, manufactures and commercializes bio therapeutic solutions for tissue repair and regeneration, is a Venture Partner at aMoon, a HealthTech and Life Sciences investment fund with Scinai's former controlling shareholder Mr. Marius Nacht as the anchor investor, and advises companies in the healthcare arena. Mr. Moed received his BA in history from Columbia University in New York City in 1985. - Samuel Moed在过去六年中担任百时美施贵宝公司（Bristol Myers Squibb“；BMS”；）的公司战略高级副总裁，，该公司是一家专注于创新疗法的全球性生物制药公司，他在该公司领导公司的战略方向，并与其所有主要业务、职能和地区保持密切联系。此前，Moed先生监管BMS&8217；s Worldwide Pharmaceuticals Group的战略，包括一系列全球战略举措，并管理战略联盟的全球投资组合。他还领导了多家企业，包括美国制药公司总裁和WW消费者梦百合总裁。Moed先生在纽约市哥伦比亚大学（Columbia University）获得历史学文学学士学位。
- Samuel Moed joined the board of directors in 2020. Mr. Moed is a healthcare executive with over 35 years of experience. He was for seven years Head of Corporate Strategy at Bristol Myers Squibb ("BMS"), a global biopharma company, until his retirement in 2020. Prior to that role, Mr. Moed was Head of Strategy Worldwide Pharma, President of US Pharma and President of the WW Consumer Health care Business at BMS. In addition to Scinai, Mr. Moed serves on the board of Mediwound Ltd., a company that develops, manufactures and commercializes bio therapeutic solutions for tissue repair and regeneration, is a Venture Partner at aMoon, a HealthTech and Life Sciences investment fund with Scinai's former controlling shareholder Mr. Marius Nacht as the anchor investor, and advises companies in the healthcare arena. Mr. Moed received his BA in history from Columbia University in New York City in 1985.
- Amir Reichman
-
Amir Reichman自2021年起担任公司首席执行官。截至2026年3月31日，Reichman先生还担任公司子公司Scinai Biopharma Services Ltd.的首席执行官。在加入公司之前，Reichman先生于2017年12月至2021年3月期间担任比利时GSK Vaccines（“GSK”）的全球疫苗工程核心技术和资产管理主管。在此之前，他曾于2015年9月至2017年11月担任GSK疫苗供应链高级总监。在GSK之前，Reichman先生曾于2011年至2015年在北卡罗来纳州霍利斯普林斯的诺华疫苗和诊断有限公司（“诺华”）全球疫苗价值链管理组织内担任各种领导职务，职责日益增加，此前GSK收购了诺华疫苗。Reichman先生也是NeuroDerm Ltd.（“NeuroDerm”）的创始团队之一，这是一家以色列公司，专注于治疗帕金森病的药物装置组合产品，该公司于2017年被三菱田边制药公司收购。他曾担任NeuroDerm的第一位员工，并在2009年之前担任高级科学家。Reichman先生拥有内盖夫本古里安大学生物技术工程硕士学位和宾夕法尼亚大学沃顿商学院金融和医疗保健管理MBA学位。
Amir Reichman has served as Chief Executive Officer of the Company since 2021. As of March 31, 2026, Mr. Reichman also serves as Chief Executive Officer of the Company's subsidiary, Scinai Biopharma Services Ltd. Prior to joining the Company, Mr. Reichman served as Head of Global Vaccines Engineering Core Technologies and Asset Management at GSK Vaccines ("GSK") in Belgium from December 2017 to March 2021. Before that, he served as Senior Director of Vaccines Supply Chain at GSK from September 2015 to November 2017.Prior to GSK, Mr. Reichman held various leadership roles of increasing responsibility within the Global Vaccines Value Chain Management organization of Novartis Vaccines and Diagnostics Ltd. ("Novartis") in Holly Springs, North Carolina from 2011 to 2015, prior to the acquisition of Novartis Vaccines by GSK. Mr. Reichman was also among the founding team of NeuroDerm Ltd. ("NeuroDerm"), an Israeli company focused on drug device combination products for the treatment of Parkinson's disease, which was acquired by Mitsubishi Tanabe Pharma Corporation in 2017. He served as NeuroDerm's first employee and as a Senior Scientist until 2009. Mr. Reichman holds an M.Sc. in Biotechnology Engineering from Ben Gurion University of the Negev and an MBA in Finance and Health Care Management from the Wharton School of the University of Pennsylvania. - Amir Reichman自2021年起担任公司首席执行官。截至2026年3月31日，Reichman先生还担任公司子公司Scinai Biopharma Services Ltd.的首席执行官。在加入公司之前，Reichman先生于2017年12月至2021年3月期间担任比利时GSK Vaccines（“GSK”）的全球疫苗工程核心技术和资产管理主管。在此之前，他曾于2015年9月至2017年11月担任GSK疫苗供应链高级总监。在GSK之前，Reichman先生曾于2011年至2015年在北卡罗来纳州霍利斯普林斯的诺华疫苗和诊断有限公司（“诺华”）全球疫苗价值链管理组织内担任各种领导职务，职责日益增加，此前GSK收购了诺华疫苗。Reichman先生也是NeuroDerm Ltd.（“NeuroDerm”）的创始团队之一，这是一家以色列公司，专注于治疗帕金森病的药物装置组合产品，该公司于2017年被三菱田边制药公司收购。他曾担任NeuroDerm的第一位员工，并在2009年之前担任高级科学家。Reichman先生拥有内盖夫本古里安大学生物技术工程硕士学位和宾夕法尼亚大学沃顿商学院金融和医疗保健管理MBA学位。
- Amir Reichman has served as Chief Executive Officer of the Company since 2021. As of March 31, 2026, Mr. Reichman also serves as Chief Executive Officer of the Company's subsidiary, Scinai Biopharma Services Ltd. Prior to joining the Company, Mr. Reichman served as Head of Global Vaccines Engineering Core Technologies and Asset Management at GSK Vaccines ("GSK") in Belgium from December 2017 to March 2021. Before that, he served as Senior Director of Vaccines Supply Chain at GSK from September 2015 to November 2017.Prior to GSK, Mr. Reichman held various leadership roles of increasing responsibility within the Global Vaccines Value Chain Management organization of Novartis Vaccines and Diagnostics Ltd. ("Novartis") in Holly Springs, North Carolina from 2011 to 2015, prior to the acquisition of Novartis Vaccines by GSK. Mr. Reichman was also among the founding team of NeuroDerm Ltd. ("NeuroDerm"), an Israeli company focused on drug device combination products for the treatment of Parkinson's disease, which was acquired by Mitsubishi Tanabe Pharma Corporation in 2017. He served as NeuroDerm's first employee and as a Senior Scientist until 2009. Mr. Reichman holds an M.Sc. in Biotechnology Engineering from Ben Gurion University of the Negev and an MBA in Finance and Health Care Management from the Wharton School of the University of Pennsylvania.
- Jay Green
-
Jay Green于2022年加入董事会。他目前是一家总部位于加拿大的医疗保健服务公司的一家私人控股公司的首席财务官，自2022年1月起担任该职务。在此之前，他在GSK完成了19年的职业生涯，在GSK的消费者医疗保健、药品和疫苗三项业务以及企业发展中担任多个进步的领导职务。他还领导了GSK的全球企业资源规划（ERP）计划，这是该公司历史上最大的IT赋能业务转型计划之一。Green先生曾于2014年至2020年担任GSK全球疫苗业务高级副总裁、财务和首席财务官。在2020年和2021年，格林先生担任全球疫苗和免疫联盟COVAX的顾问角色，这是一项支持公平分配COVID 19疫苗的国际倡议。他是一名特许专业会计师，拥有加拿大安大略省滑铁卢大学会计学硕士学位。
Jay Green joined the board of directors in 2022. He is currently the Chief Financial Officer of a privately held, Canadian based healthcare services company, a role that he has held since January 2022. Prior to this, he completed a 19 year career with GSK across several progressive leadership positions in GSK's three businesses of consumer healthcare, pharmaceuticals, and vaccines, as well as corporate development. He also led GSK's global enterprise resource planning (ERP) program, one of the largest IT enabled business transformation programs in the company's history. Mr. Green served from 2014 to 2020 as Senior Vice President, Finance and CFO of GSK's global vaccines business. In 2020 and 2021, Mr. Green served in an advisory role to Gavi for COVAX, an international initiative to support equitable distribution of COVID 19 vaccines. He is a Chartered Professional Accountant who holds a Master of Accounting from the University of Waterloo, Ontario, Canada. - Jay Green于2022年加入董事会。他目前是一家总部位于加拿大的医疗保健服务公司的一家私人控股公司的首席财务官，自2022年1月起担任该职务。在此之前，他在GSK完成了19年的职业生涯，在GSK的消费者医疗保健、药品和疫苗三项业务以及企业发展中担任多个进步的领导职务。他还领导了GSK的全球企业资源规划（ERP）计划，这是该公司历史上最大的IT赋能业务转型计划之一。Green先生曾于2014年至2020年担任GSK全球疫苗业务高级副总裁、财务和首席财务官。在2020年和2021年，格林先生担任全球疫苗和免疫联盟COVAX的顾问角色，这是一项支持公平分配COVID 19疫苗的国际倡议。他是一名特许专业会计师，拥有加拿大安大略省滑铁卢大学会计学硕士学位。
- Jay Green joined the board of directors in 2022. He is currently the Chief Financial Officer of a privately held, Canadian based healthcare services company, a role that he has held since January 2022. Prior to this, he completed a 19 year career with GSK across several progressive leadership positions in GSK's three businesses of consumer healthcare, pharmaceuticals, and vaccines, as well as corporate development. He also led GSK's global enterprise resource planning (ERP) program, one of the largest IT enabled business transformation programs in the company's history. Mr. Green served from 2014 to 2020 as Senior Vice President, Finance and CFO of GSK's global vaccines business. In 2020 and 2021, Mr. Green served in an advisory role to Gavi for COVAX, an international initiative to support equitable distribution of COVID 19 vaccines. He is a Chartered Professional Accountant who holds a Master of Accounting from the University of Waterloo, Ontario, Canada.
- Mark Germain
-
Mark Germain，2007年5月，Germain先生成为本公司董事。2007年5月至2009年2月，Germain先生担任董事会联合主席。五年以上，Germain先生成为主要服务于生物技术和生命科学行业的商业银行家。他曾在生物技术领域20多所公司中担任创始人，董事，董事会主席和投资者并帮助他们中的许多安排公司建立合作关系，获取技术，进入了兼并和收购，并执行融资和上市交易。1975年，他从New York University School of Law 法学院优等生协会中毕业；1986年，他也是一所纽约法律公司的合伙人，实践公司和证卷法律。从那以后，直到1991年进入生物技术领域，他任职于高级执行职位，包括上市公司总裁，直到其在1991年被出售。除了担任公司主管之外，Germain先生是上市交易ChromaDex, Inc. CDXB.OB的主管。Germain先生也在以下公司担任董事；ll Innovations, Inc., Omnimmune Corp. 和Collexis Holdings, Inc.他也是许多私人生物技术领域公司的董事和联合创始人。
Mark Germain joined the Board of Directors of the Company in 2018 and has served as Chairman of the Board since 2019. As of March 31, 2026, Mr. Germain also serves as Chairman of the Board of the Company's subsidiary, Scinai Biopharma Services Ltd. Mr. Germain has been involved as a founder, director, chairman and investor in over twenty biotechnology companies and has assisted many of them in arranging corporate partnerships, acquiring technology, executing mergers and acquisitions, and completing financing and public offering transactions. Mr. Germain graduated from New York University School of Law in 1975, where he was a member of the Order of the Coif, and was a partner at a New York law firm specializing in corporate and securities law until 1986. From 1986 to 1991, he served in senior executive roles, including as president of a public company that was subsequently sold. In addition to serving as Chairman of the Company, Mr. Germain is a Managing Director at The Aentib Group, a boutique merchant bank, and previously served on the board of Pluristem Therapeutics from 2007 through June 2022, including as Co Chairman and lead independent director. He is also a co founder and director of a number of private companies in and outside the biotechnology sector. - Mark Germain，2007年5月，Germain先生成为本公司董事。2007年5月至2009年2月，Germain先生担任董事会联合主席。五年以上，Germain先生成为主要服务于生物技术和生命科学行业的商业银行家。他曾在生物技术领域20多所公司中担任创始人，董事，董事会主席和投资者并帮助他们中的许多安排公司建立合作关系，获取技术，进入了兼并和收购，并执行融资和上市交易。1975年，他从New York University School of Law 法学院优等生协会中毕业；1986年，他也是一所纽约法律公司的合伙人，实践公司和证卷法律。从那以后，直到1991年进入生物技术领域，他任职于高级执行职位，包括上市公司总裁，直到其在1991年被出售。除了担任公司主管之外，Germain先生是上市交易ChromaDex, Inc. CDXB.OB的主管。Germain先生也在以下公司担任董事；ll Innovations, Inc., Omnimmune Corp. 和Collexis Holdings, Inc.他也是许多私人生物技术领域公司的董事和联合创始人。
- Mark Germain joined the Board of Directors of the Company in 2018 and has served as Chairman of the Board since 2019. As of March 31, 2026, Mr. Germain also serves as Chairman of the Board of the Company's subsidiary, Scinai Biopharma Services Ltd. Mr. Germain has been involved as a founder, director, chairman and investor in over twenty biotechnology companies and has assisted many of them in arranging corporate partnerships, acquiring technology, executing mergers and acquisitions, and completing financing and public offering transactions. Mr. Germain graduated from New York University School of Law in 1975, where he was a member of the Order of the Coif, and was a partner at a New York law firm specializing in corporate and securities law until 1986. From 1986 to 1991, he served in senior executive roles, including as president of a public company that was subsequently sold. In addition to serving as Chairman of the Company, Mr. Germain is a Managing Director at The Aentib Group, a boutique merchant bank, and previously served on the board of Pluristem Therapeutics from 2007 through June 2022, including as Co Chairman and lead independent director. He is also a co founder and director of a number of private companies in and outside the biotechnology sector.
高管简历
中英对照 | 中文 | 英文- Elad Mark
Elad Mark于2018年加入公司，担任网站负责人，自2019年9月起担任首席运营官。作为首席运营官，他监管BiondVax的制造设施和规模扩大以及技术转让活动，包括潜在的未来CMO&8217；S.在加入BiondVax之前，Mark先生曾在诺华公司（Novartis）任职三年多，担任TPM技术流程经理和新加坡一家大型生物设施的区域领导流程，8亿美元投资于生物制剂设施，专注于基于细胞培养技术的原料药制造，旨在支持包括单克隆抗体在内的潜在新产品的临床和商业生产，以帮助自身免疫，呼吸和肿瘤疾病患者。在此之前，Mark先生担任Biopharmax Group的工程部主管，该公司专注于制药领域的EPCM（工程，采购，建筑和管理）。Mark先生是一位首席生物工艺工程师，拥有超过12年的生物技术工程经验，拥有不同的项目阶段，包括可行性研究，概念和细节设计，调试，资格和过程验证。Mark先生持有B.SC.Tel Aviv的Afeka Academic College of Engineering工程学士学位和the Open University of Israel工商管理硕士学位。
Elad Mark joined the Company in 2018 as Site Head and served as Chief Operating Officer from September 2019. As of March 31, 2026, Mr. Mark serves as Chief Business Officer and Chief Technology Officer (CBO/CTO) of the Company's subsidiary, Scinai Biopharma Services Ltd., where he is responsible for business development, sales and marketing, program management, and cross site engineering and technical functions across the CDMO platform. In this role, Mr. Mark focuses on commercial growth, client engagement and the integration of technical and operational capabilities across the subsidiary's manufacturing sites. Prior to joining the Company, Mr. Mark served for more than three years at Novartis as Technical Process Manager and Area Lead Process for the establishment of a large scale biologics manufacturing facility in Singapore, a $800 million investment focused on drug substance manufacturing based on cell culture technology, supporting both clinical and commercial production of monoclonal antibodies for autoimmune, respiratory and oncology indications. Before that, Mr. Mark served as Head of the Engineering Department at Biopharmax Group, a company specializing in engineering, procurement, construction and management (EPCM) services for the pharmaceutical industry. Mr. Mark is a bioprocess engineer with over 15 years of experience across biotechnology engineering and manufacturing projects, including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Mr. Mark holds a B.Sc. in Engineering from Afeka Academic College of Engineering in Tel Aviv and an MBA from the Open University of Israel.- Elad Mark于2018年加入公司，担任网站负责人，自2019年9月起担任首席运营官。作为首席运营官，他监管BiondVax的制造设施和规模扩大以及技术转让活动，包括潜在的未来CMO&8217；S.在加入BiondVax之前，Mark先生曾在诺华公司（Novartis）任职三年多，担任TPM技术流程经理和新加坡一家大型生物设施的区域领导流程，8亿美元投资于生物制剂设施，专注于基于细胞培养技术的原料药制造，旨在支持包括单克隆抗体在内的潜在新产品的临床和商业生产，以帮助自身免疫，呼吸和肿瘤疾病患者。在此之前，Mark先生担任Biopharmax Group的工程部主管，该公司专注于制药领域的EPCM（工程，采购，建筑和管理）。Mark先生是一位首席生物工艺工程师，拥有超过12年的生物技术工程经验，拥有不同的项目阶段，包括可行性研究，概念和细节设计，调试，资格和过程验证。Mark先生持有B.SC.Tel Aviv的Afeka Academic College of Engineering工程学士学位和the Open University of Israel工商管理硕士学位。
- Elad Mark joined the Company in 2018 as Site Head and served as Chief Operating Officer from September 2019. As of March 31, 2026, Mr. Mark serves as Chief Business Officer and Chief Technology Officer (CBO/CTO) of the Company's subsidiary, Scinai Biopharma Services Ltd., where he is responsible for business development, sales and marketing, program management, and cross site engineering and technical functions across the CDMO platform. In this role, Mr. Mark focuses on commercial growth, client engagement and the integration of technical and operational capabilities across the subsidiary's manufacturing sites. Prior to joining the Company, Mr. Mark served for more than three years at Novartis as Technical Process Manager and Area Lead Process for the establishment of a large scale biologics manufacturing facility in Singapore, a $800 million investment focused on drug substance manufacturing based on cell culture technology, supporting both clinical and commercial production of monoclonal antibodies for autoimmune, respiratory and oncology indications. Before that, Mr. Mark served as Head of the Engineering Department at Biopharmax Group, a company specializing in engineering, procurement, construction and management (EPCM) services for the pharmaceutical industry. Mr. Mark is a bioprocess engineer with over 15 years of experience across biotechnology engineering and manufacturing projects, including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Mr. Mark holds a B.Sc. in Engineering from Afeka Academic College of Engineering in Tel Aviv and an MBA from the Open University of Israel.
- Uri Ben Or
Uri Ben Or is Cnbx Pharmaceuticals Inc. CFO。Ben-Or先生是一名执业注册会计师、工商管理硕士，在生命科学和医疗器械行业的公立和私立公司拥有15年以上的CFO经验。Uri在TASE上交易的公共生命科学公司拥有丰富的专业知识。此外，Uri在美国、欧洲和以色列的初创公司和全球上市公司拥有强大的财务、运营和业务发展背景，包括制定公司结构和筹资方面的战略政策和指导。
Uri Ben Or has served as Chief Financial Officer of the Company since 2007. As of March 31, 2026, Mr. Ben Or also serves as Chief Financial Officer of the Company's subsidiary, Scinai Biopharma Services Ltd. In January 2007, Mr. Ben Or founded CFO Direct, through which he provides financial management services to the Company. Mr. Ben Or has over 20 years of experience in corporate finance, accounting, mergers and acquisitions and public offerings, and has served as chief financial officer of multiple life sciences companies listed on the Tel Aviv Stock Exchange, Nasdaq and over the counter markets. Mr. Ben Or holds a B.A. in Business from the College of Administration, an M.B.A. from Bar Ilan University and is a certified public accountant in Israel.- Uri Ben Or is Cnbx Pharmaceuticals Inc. CFO。Ben-Or先生是一名执业注册会计师、工商管理硕士，在生命科学和医疗器械行业的公立和私立公司拥有15年以上的CFO经验。Uri在TASE上交易的公共生命科学公司拥有丰富的专业知识。此外，Uri在美国、欧洲和以色列的初创公司和全球上市公司拥有强大的财务、运营和业务发展背景，包括制定公司结构和筹资方面的战略政策和指导。
- Uri Ben Or has served as Chief Financial Officer of the Company since 2007. As of March 31, 2026, Mr. Ben Or also serves as Chief Financial Officer of the Company's subsidiary, Scinai Biopharma Services Ltd. In January 2007, Mr. Ben Or founded CFO Direct, through which he provides financial management services to the Company. Mr. Ben Or has over 20 years of experience in corporate finance, accounting, mergers and acquisitions and public offerings, and has served as chief financial officer of multiple life sciences companies listed on the Tel Aviv Stock Exchange, Nasdaq and over the counter markets. Mr. Ben Or holds a B.A. in Business from the College of Administration, an M.B.A. from Bar Ilan University and is a certified public accountant in Israel.
- Amir Reichman
Amir Reichman自2021年起担任公司首席执行官。截至2026年3月31日，Reichman先生还担任公司子公司Scinai Biopharma Services Ltd.的首席执行官。在加入公司之前，Reichman先生于2017年12月至2021年3月期间担任比利时GSK Vaccines（“GSK”）的全球疫苗工程核心技术和资产管理主管。在此之前，他曾于2015年9月至2017年11月担任GSK疫苗供应链高级总监。在GSK之前，Reichman先生曾于2011年至2015年在北卡罗来纳州霍利斯普林斯的诺华疫苗和诊断有限公司（“诺华”）全球疫苗价值链管理组织内担任各种领导职务，职责日益增加，此前GSK收购了诺华疫苗。Reichman先生也是NeuroDerm Ltd.（“NeuroDerm”）的创始团队之一，这是一家以色列公司，专注于治疗帕金森病的药物装置组合产品，该公司于2017年被三菱田边制药公司收购。他曾担任NeuroDerm的第一位员工，并在2009年之前担任高级科学家。Reichman先生拥有内盖夫本古里安大学生物技术工程硕士学位和宾夕法尼亚大学沃顿商学院金融和医疗保健管理MBA学位。
Amir Reichman has served as Chief Executive Officer of the Company since 2021. As of March 31, 2026, Mr. Reichman also serves as Chief Executive Officer of the Company's subsidiary, Scinai Biopharma Services Ltd. Prior to joining the Company, Mr. Reichman served as Head of Global Vaccines Engineering Core Technologies and Asset Management at GSK Vaccines ("GSK") in Belgium from December 2017 to March 2021. Before that, he served as Senior Director of Vaccines Supply Chain at GSK from September 2015 to November 2017.Prior to GSK, Mr. Reichman held various leadership roles of increasing responsibility within the Global Vaccines Value Chain Management organization of Novartis Vaccines and Diagnostics Ltd. ("Novartis") in Holly Springs, North Carolina from 2011 to 2015, prior to the acquisition of Novartis Vaccines by GSK. Mr. Reichman was also among the founding team of NeuroDerm Ltd. ("NeuroDerm"), an Israeli company focused on drug device combination products for the treatment of Parkinson's disease, which was acquired by Mitsubishi Tanabe Pharma Corporation in 2017. He served as NeuroDerm's first employee and as a Senior Scientist until 2009. Mr. Reichman holds an M.Sc. in Biotechnology Engineering from Ben Gurion University of the Negev and an MBA in Finance and Health Care Management from the Wharton School of the University of Pennsylvania.- Amir Reichman自2021年起担任公司首席执行官。截至2026年3月31日，Reichman先生还担任公司子公司Scinai Biopharma Services Ltd.的首席执行官。在加入公司之前，Reichman先生于2017年12月至2021年3月期间担任比利时GSK Vaccines（“GSK”）的全球疫苗工程核心技术和资产管理主管。在此之前，他曾于2015年9月至2017年11月担任GSK疫苗供应链高级总监。在GSK之前，Reichman先生曾于2011年至2015年在北卡罗来纳州霍利斯普林斯的诺华疫苗和诊断有限公司（“诺华”）全球疫苗价值链管理组织内担任各种领导职务，职责日益增加，此前GSK收购了诺华疫苗。Reichman先生也是NeuroDerm Ltd.（“NeuroDerm”）的创始团队之一，这是一家以色列公司，专注于治疗帕金森病的药物装置组合产品，该公司于2017年被三菱田边制药公司收购。他曾担任NeuroDerm的第一位员工，并在2009年之前担任高级科学家。Reichman先生拥有内盖夫本古里安大学生物技术工程硕士学位和宾夕法尼亚大学沃顿商学院金融和医疗保健管理MBA学位。
- Amir Reichman has served as Chief Executive Officer of the Company since 2021. As of March 31, 2026, Mr. Reichman also serves as Chief Executive Officer of the Company's subsidiary, Scinai Biopharma Services Ltd. Prior to joining the Company, Mr. Reichman served as Head of Global Vaccines Engineering Core Technologies and Asset Management at GSK Vaccines ("GSK") in Belgium from December 2017 to March 2021. Before that, he served as Senior Director of Vaccines Supply Chain at GSK from September 2015 to November 2017.Prior to GSK, Mr. Reichman held various leadership roles of increasing responsibility within the Global Vaccines Value Chain Management organization of Novartis Vaccines and Diagnostics Ltd. ("Novartis") in Holly Springs, North Carolina from 2011 to 2015, prior to the acquisition of Novartis Vaccines by GSK. Mr. Reichman was also among the founding team of NeuroDerm Ltd. ("NeuroDerm"), an Israeli company focused on drug device combination products for the treatment of Parkinson's disease, which was acquired by Mitsubishi Tanabe Pharma Corporation in 2017. He served as NeuroDerm's first employee and as a Senior Scientist until 2009. Mr. Reichman holds an M.Sc. in Biotechnology Engineering from Ben Gurion University of the Negev and an MBA in Finance and Health Care Management from the Wharton School of the University of Pennsylvania.